ArticleClinical interventions in aging2023
Carbapenem-Resistant
Article in Clinical interventions in aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Risk factors for carbapenem-resistantFrontiers in public health · 2026Pooled it
- Risk factors for carbapenem-resistant Klebsiella pneumoniae infection in hospitalized patients: a meta-analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- A nomogram for assessing secondary infection risk in hospitalized patients with intestinal CRE colonization: a prospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- The ESKAPE Challenge: Understanding Resistance and Exploring Alternative Treatments.Antibiotics (Basel, Switzerland) · 2026Review
- Clinical outcomes and mortality in carbapenem-resistant versus susceptible Klebsiella pneumoniae bloodstream infections in intensive care units.BMC infectious diseases · 2026Article
- Temporal Trends in Antibiotic Resistance of Klebsiella pneumoniae and Antibiotic Consumption: A Six-year Longitudinal Surveillance Study : Temporal Trends of Resistance and Consumption of Antibiotics to K. pneumoniae.Journal of epidemiology and global health · 2026Article
- Intestinal mucus acts as a nutrient source and signal forMicrobiome research reports · 2026Article
- Risk factors, resistance profiles, and clinical outcomes ofFrontiers in cellular and infection microbiology · 2026Article
- Epidemiology and genomic characteristics of carbapenem-resistant Klebsiella pneumoniae in intensive care unit from 2021 to 2024.BMC microbiology · 2025Article
- Nanomedicine approaches to enhance the effectiveness of meropenem: a strategy to tackle antimicrobial resistance.Discover nano · 2025Review
- Clinical characteristics, risk factors and prognosis ofFrontiers in cellular and infection microbiology · 2025Article
- Poor Glycemic Control in Carbapenem-ResistantInfection and drug resistance · 2025Article
- Article
- Risk Factors and Outcomes of Community-Acquired Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Risk Factors for Multidrug Resistance in Patients Infected with Carbapenem-ResistantInfection and drug resistance · 2024Article
- The prognostic value of neutrophil-to-lymphocyte ratio in adult carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Nosocomial, Healthcare-Associated, and Community-AcquiredInfection and drug resistance · 2024Article
- Analysis of Risk Factors for Carbapenem ResistantInfection and drug resistance · 2023Article
- Secondary pulmonary infection and co-infection in elderly COVID-19 patients during the pandemics in a tertiary general hospital in Beijing, China.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Carbapenem-resistant Material and Methods: This retrospective, single-center study included 132 patients with healthcare-associated CRKP infection (case group) and 150 patients with healthcare-associated carbapenem-susceptible Results: In the CRKP and CSKP groups, 79 (59.8%) and 80 (53.3%) patients were males, and the mean ages were 77.8 ± 7.8 and 76.6 ± 7.7 years, respectively. Diabetes mellitus (DM), malignancy, cardiovascular diseases (CVDs), surgical intervention, invasive mechanical ventilation, central venous catheter insertion, parenteral nutrition, hospitalization in the previous 6 months, antibiotic use in the previous 3 months, and exposure to cephalosporins, fluoroquinolones, and carbapenems were significantly more common in the CRKP than the CSKP group (all p < 0.05). The multivariate logistic regression analysis identified malignancy, CVDs, DM, invasive mechanical ventilation, hospitalization in the previous 6 months, ICU admission, and exposure to cephalosporins, quinolones, and carbapenems as independent risk factors for CRKP infection in older adult patients. Conclusion: DM, malignancy, CVDs, ICU admission, invasive mechanical ventilation, and exposure to ceftriaxone, fluoroquinolones, and carbapenems were independent risk factors for CRKP infection in older adult patients. The identification of risk factors for CRKP infection can help to prevent and treat CRKP infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.